A growing series of clinical trials and case series now suggest that ketamine—originally used as an anesthetic agent—potentially offers an exciting new treatment option for severe depression. Increasing numbers of studies show that ketamine can provide prompt relief for many depressed patients, including those with severe treatment-refractory depression. Although the effects of a single treatment are commonly short-lived, multiple infusion protocols may offer sustained relief. The uniquely rapid onset of antidepressant action raises the potential for ketamine use in a variety of clinical situations, including the prevention or shortening of hospital stays, the treatment of acute suicidal ideation, and the facilitation of medication crossovers. Ketamine, in combination with other multimodal treatment approaches, including psychotherapy, may further augment response effect and duration. Promises of efficacy have led to increasingly unbridled use to treat a variety of psychiatric disorders, with diverse approaches and treatment environments, despite inadequate data demonstrating the true clinical efficacy and safety of the various protocols or a thorough understanding of mechanisms of action. This article briefly reviews the history of ketamine's development as a potential antidepressant, current hypotheses related to its mechanisms of action, and existing evidence for its safety and efficacy with a focus on clinicians' interests.

There is clear evidence highlighting the need for new and more effective treatments for depression. Up to one third of patients do not respond to typical treatment strategies. When effective, responses can take weeks to months, and even then relapse rates remain unacceptably high (1). These shortcomings are further amplified by the significant morbidity and mortality associated with depression and their impact on individuals, families and society. To date, nearly all U.S. Food and Drug Administration (FDA)-approved medications to treat depression have developed from the same monoamine-based hypotheses dominating the field since the 1960s, with little success in identifying other effective pharmacological approaches. Thus considered, there is deserved enthusiasm about emerging evidence suggesting that ketamine, a medication initially approved by the FDA in 1970 as an anesthetic agent, can induce rapid-onset antidepressant effects in a substantial proportion of patients.

This combination of unmet need for more effective and rapidly acting antidepressant treatments, with mounting evidence demonstrating ketamine’s rapid antidepressant properties, has led to exponential growth of its off-label use (2). The use of ketamine is outpacing the published data demonstrating the efficacy and safety of the treatment. In this article, we attempt to provide a brief overview of the events leading to the discovery of ketamine’s antidepressant effects, review the current data surrounding the efficacy and safety of the drug, and outline a rational path forward for practicing clinicians.

### THE PATHOPHYSIOLOGY OF DEPRESSION: THE GLUTAMATE THEORY

The monoamine theory of depression has historically dominated our pharmacologic approaches. Studies examining the physiological consequences of chronic stress have provided the field with new insights into additional pathogenic and pathophysiological mechanisms of depression. The brain’s response to acute stress may serve an adaptive role in survival; however, exposure to chronic stress may lead to long-term synaptic injury and dysfunction (3). Chronic and severe stress are associated with dysregulation of the hippocampal-pituitary-adrenal axis, maladaptive changes in neurotransmitter signaling, alterations in inflammatory pathways, and dysregulation of neurotrophic factor signaling—all capable of altering neuroplasticity and producing maladaptive changes in brain structure and function.

A growing series of studies have demonstrated the critical role of glutamate in modulating neuroplasticity and suggest that stress-induced changes in this system's function may contribute to the neurobiology of mood disorders (3, 4). Work dating back to the early 1990s demonstrated specific changes in the function of the glutamatergic N-methyl-d-aspartate (NMDA) receptor following periods of stress exposure and that drugs acting as NMDA antagonists could produce antidepressant-like effects in rodent models (5). Chronic stress also affects glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, closely associated with the regulation of neurotrophic
A: Glutamate surge model of the absence of ketamine. Under normal physiological conditions, activation of NMDA receptors on inhibitory GABAergic interneurons (1) tonically inhibits release of presynaptic glutamate (2), resulting in minimal activation of postsynaptic AMPA receptors (3), low levels of BDNF expression, and mTOR activation to drive baseline local protein synthesis. Under the desuppression-of-translation model, low levels of spontaneous stimulation of postsynaptic NMDA receptors cause an activation of elongation factor 2 kinase (5) and subsequent phosphorylation of elongation factor 2, resulting in inhibition of local protein synthesis, including BDNF expression (6). B: Glutamate surge model of the presence of subanesthetic doses of ketamine. This model proposes that subanesthetic doses of ketamine selectively block NMDA receptor function on inhibitory GABAergic interneurons (1), thus causing a surge in glutamate release (2) and an increased phasic activation of the postsynaptic AMPA receptors (3) that results in increased local protein and BDNF expression (4). This is believed to result in further AMPA activation and local increases in neuroplasticity and synaptogenesis (5). The desuppression model suggests that subanesthetic doses of ketamine are selectively blocking the function of NMDA receptors at rest, responding to spontaneous glutamate release (6). This response results in decreased activation of elongation factor 2 kinase, dephosphorylation and activation of elongation factor 2 (7), and increased levels of local protein synthesis, including BDNF (4). This would result in an increased insertion of AMPA receptors and generate the same downstream effects as proposed above on BDNF, local protein synthesis and synaptogenesis (3–5). More recently, data generated with hydroxynorketamine and other novel compounds suggest that NMDA receptor blockade may not be necessary to achieve the cellular response associated with ketamine. Instead, this model proposes that the effects of these drugs are produced by either non-NMDA–mediated stimulated release of presynaptic glutamate (2) or direct activation of the postsynaptic AMPA receptors (3) that then initiate the same downstream cascade of events leading to increased neuroplasticity (4 and 5). Abbreviations: BDNF, brain-derived neurotrophic factor; mTOR, mechanistic target of rapamycin; eEF2, eukaryotic elongation factor 2; eEF-2K, eukaryotic elongation factor 2 kinase; HNK, hydroxynorketamine

KETAMINE PHARMACOLOGY

Ketamine acts as a high-affinity, noncompetitive, open-channel NMDA receptor blocker. The NMDA receptor is an ionotropic (ligand-gated transmembrane ion channel) receptor within the glutamatergic neurotransmitter system, along with AMPA and kainate receptors. Glutamate serves as the major excitatory neurotransmitter in the central nervous system. Its roles in neuroplasticity, cognition, memory, and learning are thought to be mediated in large part through modulation of the NMDA receptors, which are present ubiquitously throughout the brain (13). As a consequence of the NMDA receptor’s central role in brain function, the receptor is highly regulated by a variety of physiological factors, which results in a highly complex receptor pharmacology.

When functioning correctly, glutamate binds and causes the NMDA receptor channel to open, allowing calcium ions to cross the neuronal membrane, which only occurs with the cobinding of glycine or serine (or both) in the correct local pH (Figure 1A). These strict physiological conditions serve to maintain optimal signal-to-noise detection within the nervous system and prevent neuronal excitotoxicity. Ketamine blocks the NMDA receptor channel, preventing ion influx and attenuating the generation of action potentials in neurons containing NMDA receptors.
While ketamine's effects on the NMDA receptor are believed to be the central mechanism mediating the more immediate hypnotic and analgesic effects of the drug, there are several other molecular actions that may help mediate its effects on consciousness, pain, cognition, and possibly depression. Examples of these mechanisms include an inhibition of the hyperpolarization-activated cationic channel (HCN1) (14), activation of the nitric oxide-cyclic guanosine-monophosphate (cGMP) pathway (15), modulation of opioid receptors (16), and inhibition of nicotinic acetylcholine receptors (17). In addition, ketamine also has reported downstream effects on monoaminergic (18) and neuropeptide signaling (19), as well as inflammation (20).

Ketamine has a notably short half-life, ranging from 100 to 200 minutes (as reported at the 36th Meeting of the WHO Expert Committee on Drug Dependence in Geneva, Switzerland, June 16–20, 2014), and is completely metabolized within a few hours of dosing, suggesting that antidepressant mechanisms are tied to downstream effects of the drug. Hypotheses regarding ketamine's more immediate pharmacological effects have been largely based on rodent microdialysis and electrophysiological studies that suggested that subanesthetic doses of ketamine and other NMDA-receptor antagonists have selective activity on NMDA receptors located on inhibitory GABAergic interneurons, especially those in the medial prefrontal cortex and the hippocampus (21–23). Blocking NMDA receptor-related GABAergic interneuron activity, thereby releasing tonic inhibition of glutamnergic neurons, is thought to generate a selective increase in glutamate release, or “glutamate surge,” in specific brain regions (Figure 1B). Several lines of research now suggest that this glutamate surge is associated with ketamine's antidepressant-like response in rodent models (3, 24, 25); however, the data remain far from conclusive.

The next step in the proposed cascade is believed to be the region-specific activation of postsynaptic AMPA receptors. Several preclinical studies, using AMPA-receptor antagonists such as NBQX to block the antidepressant-like effects of ketamine and other glutamate-modulating drugs, suggest that this is a necessary element of ketamine's antidepressant mechanism (26–28). The need for AMPA activation is one of the most consistent findings in the preclinical literature and has been reported in multiple studies of drugs associated with a rapid onset of antidepressant activity (29–33). There remains, however, some discrepancy on whether effects on glutamate release are necessary (32) and whether action at the NMDA receptor is a necessary component of the drug's antidepressant action at all (29).

Believed to be a consequence of the increased activation of AMPA glutamate receptors, rapid increases in regional brain metabolism have been shown in several studies with subanesthetic ketamine administration in rodents and humans (34–37), most prominent in several regions closely associated with mood and depressive symptomology. Emerging evidence now suggests that there are rapid neuroplastic changes in several of these brain regions following ketamine administration in rodent models in the form of increased dendritic spine densities (3), electrophysiological measures of connectivity (38), and imaging measures of functional connectivity (39). These structural and cytoarchitectural changes are believed to be correlates to several recent findings that suggest dramatic changes in brain connectivity in humans, downstream from the immediate pharmacological effects (25, 40, 41).

**CLINICAL PERSPECTIVES**

Inspired by the emerging preclinical data outlined earlier, the first study to specifically assess ketamine's utility in treating major depressive disorder was performed by Krystal and colleagues at Yale University in the late 1990s (42). The dose, 0.5 mg/kg infused over 40 minutes, was chosen on the basis of previous studies by this group showing that this dose had significant effects on cognition and perception but still allowed the subject to remain awake enough to answer questions and perform simple tasks (43). The large magnitude and rapid onset of antidepressant effects observed in the study were surprising. Notably, although the study generated immediate interest in the glutamatergic system as a novel target for antidepressant development, it took another 6 years before these findings were replicated (44). Since this time, there have been numerous small replication studies yielding largely consistent findings regarding the rapid antidepressant effects of a single subanesthetic dose of ketamine (45, 46). These results, combined with the tremendous unmet need for more effective treatments, have led to a significant increase in the off-label use of ketamine for the treatment of depression and other psychiatric disorders (2). The remaining sections of this article outline and highlight the many unresolved questions and concerns related to this treatment.

**DOsing**

There has been astonishingly little research attempting to identify optimal dosing strategies for ketamine. As noted earlier, the original study demonstrating ketamine's antidepressant actions (42) used a dose of 0.5 mg/kg intravenously (i.v.) delivered over 40 minutes, based on the drug's transient effects on cognition and perception, without consideration of optimal dosing for antidepressant effects. Interestingly, evidence now suggests that ketamine has a unique inverted U-shaped dose-response relationship in rodent models, which is most effective at moderate subanesthetic doses (24). However, remarkably, there have been relatively few dose-optimization studies performed until recently.

A few small pilot studies have attempted assess ketamine dose titration, but these studies are very challenging to interpret, given small sample sizes and complicated study designs (47–49). Two larger controlled studies examining the effects of various subanesthetic doses of ketamine have recently been completed. The first found a significant dose-
related effect of ketamine, whereby a 0.5-mg/kg dose appeared more efficacious than a 0.2-mg/kg dose of ketamine in treating more severely depressed patients (50). The second, a multisite study funded through the National Institute for Mental Health’s Rapidly-Acting Treatments for Treatment-Resistant Depression mechanism, attempted to explore the antidepressant effects of ketamine across a range of doses (0.1, 0.2, 0.5, and 1 mg/kg compared with a midazolam control) in a between-subjects design (presented in 2017 at the annual meeting of the American Society of Clinical Psychopharmacology). The study clearly demonstrated the superior effect of ketamine compared with midazolam, but because of the limited power of the study, it was unable to statistically identify an optimal dose. However, the 0.5-mg/kg dose numerically gave the largest and most consistent signal of antidepressant efficacy across multiple outcome measures. In light of the limited high-quality data that are currently available, it is difficult to provide clear guidance on optimal dosing, but increasing evidence supports that a dose-response relationship of some sort does exist. A survey of providers suggests that a significant proportion of clinicians offering the treatment are continuing to use the 0.5-mg/kg dosing i.v. over 40 minutes (2).

The question of long-term effectiveness remains a challenge in assessing the clinical value of ketamine. The large majority of the randomized controlled studies performed to date have used a single dose of the drug. While the antidepressant effects of single dosing may be sustained for days to weeks in many patients, near-complete relapse of symptoms is common when patients are followed for extended periods of time (51), promoting the exploration of approaches capable of sustaining or prolonging the effects. There are now several case series and clinical reports suggesting that the antidepressant effects can be sustained for periods of several months with repeated administration of ketamine (51–54), which we have also seen in our clinical practice (55). However, relatively little high-quality–controlled data have been published to demonstrate the sustained effectiveness of the drug. A single randomized placebo-controlled study has evaluated the effects of the frequency of repeated ketamine dosing (56). The findings from this study of 67 patients suggested that a dosing of twice per week was just as effective as thrice per week, and both regimens showed large sustained effects for the two weeks of randomized dosing compared with a saline placebo. In an open-label continuation phase of this study, the large majority of the patients maintained their response for at least an additional two weeks with ongoing treatment. The results from the recent survey of providers suggest that the large majority of clinicians are administering doses of the medication either two or three times a week to initiate treatment (2); however, there is no clear consensus on the optimal dosing strategy.

The optimal route of administration is also unclear. The original studies used dosing i.v., and the large majority of published studies to date have continued to use this route. However, alternative routes have been explored. An early report by Lapidus et al. (57) showed the potential use of the intranasal administration of ketamine for major depressive disorder. The ease of use and rapid absorption of the drug makes this route appealing, but problems controlling bioavailability (58) and tolerability (59) do present challenges. More recently, intranasal administration of esketamine has been shown to be effective in a randomized, placebo-controlled study (60), and a large phase-III program is under way to evaluate the efficacy and safety of intranasal esketamine that should provide results in the near future. Other studies have explored administration via subcutaneous injections (47) and oral administration (61, 62). However, the volume and quality of the published data on these routes of administration remain extremely limited.

In summary, the effects of a single ketamine infusion are, unfortunately, often short-lived for most patients, which has increasingly led clinicians to provide series of infusions to prolong response. However, data supporting this specific regimen remain relatively limited and even less so for maintenance strategies. To date, we are not aware of any published controlled trials extending beyond 1 month of ongoing treatment. However, the growing number of case series and open-label reports do suggest that the antidepressant effects can be sustained with periodic repeated dosings for some patients. The risks of both single and repeated dosing are described later in the article.

OTHER INDICATIONS

Ketamine is now frequently being prescribed for off-label use as a treatment for major depression disorder. A few studies have specifically assessed the efficacy and safety of ketamine for bipolar depression (63–66). These relatively small proof-of-concept studies suggest an efficacy similar to that for its use for major depressive disorders but that may be associated with a shorter duration of antidepressant effect. Notably, the majority of these studies treated patients with bipolar disorder who were concurrently taking a mood stabilizer, either lithium or valproate.

On the basis of the proposed mechanisms of action, there is growing interest in ketamine’s potential utility in the treatment of posttraumatic stress disorder (PTSD) (67). Although several case series and a single clinical trial assessing ketamine’s efficacy in PTSD (68) suggest some clinical benefit, there are little quality data to evaluate at this time. A large study sponsored by the U.S. Department of Veterans Affairs and the U.S. Department of Defense (NCT02655692) is currently under way, with plans to evaluate the efficacy of ketamine in nearly 200 military personnel with PTSD over the next few years.

Based in part on patient reports, there is also increased interest in ketamine for treating anxiety disorders. Glue and colleagues observed what appeared to be dose-related improvements in 10 out of 12 nondepressed patients with generalized anxiety disorder, social anxiety, or both in an open-label study with subcutaneous, ascending, weekly
dosing of ketamine (69). Another small study of 18 patients evaluated a single infusion of ketamine compared with saline placebo for social anxiety in a sequential design. The authors reported a meaningful clinical response in 33% of the patients after ketamine administration, whereas there were no responders after placebo administration (70). Two studies showed mixed results with obsessive-compulsive disorder (OCD): Rodriguez and colleagues found a positive effect of ketamine in patients with OCD when comparing a single infusion of ketamine to saline within a double-blind crossover trial (71); however, a previous small, open-label study by Bloch and colleagues found no meaningful clinical benefit (72).

As may be expected, based on the proposed effects of ketamine on neuroplasticity, interest in ketamine has spread well beyond the standard psychiatric indications. Ongoing areas of interest range from chronic pain (73) to Parkinson’s disease (74), to Rett’s syndrome (75). However, the bottom line is that there are few studies with limited sample sizes to suggest clinical benefit in any of these indications at the present time, possibly beyond pain management.

Another worthy question is whether ketamine used in combination with electroconvulsive therapy (ECT) for depression can produce enhanced benefits. Researchers have hoped to find a synergistic role for ketamine in combination with ECT for major depressive disorder, either for augmentation of antidepressant effects or cognitive protection. Unfortunately, although complicated to evaluate, neither have been consistently demonstrated in study populations (76). Further studies are necessary to better evaluate the benefit of ketamine as the primary anesthetic agent, as well as the use of ketamine administered with prolonged infusion protocols for these purposes.

Last, there is an increasing amount of higher quality data to support ketamine’s effects on suicidal ideation (77–80). The existing studies suggest a rapid onset of antidepressant effects associated with ketamine treatment that may, to some extent, be independent of the drug’s effects on other symptoms of depression. An individual patient-level meta-analysis containing most of these data found ketamine to produce a moderate-to-large effect size (Cohen’s $d=0.48–0.85$) for the reduction of suicidal ideation for up to one week in duration after a single dosing (80). Interestingly, the effect was seen even after adjusting for concurrent reductions in depressive symptoms. A recently completed study with esketamine showed marked improvement in depressive symptoms and suicidal ideation in patients with major depression expressing imminent, severe suicidal ideation, behavior, or both (81). Interestingly, these benefits were seen in addition to very good response rates to placebo combined with standard-of-care treatments of these patients.

**RISKS OF USE**

Understanding the risks associated with ketamine use is an essential component of making any risk-benefit assessment. Although ketamine has well-characterized transient effects on cardiovascular, cognitive, and perceptual functions (43, 82), there are significantly less published data on the safety of repeated administrations. The acute effects on cardiovascular function suggest the need for a thorough pre-treatment physical examination to identify those at potential risk of harm and close monitoring during treatment. It also continues to limit the environment in which ketamine can be safely administered (83). Although a recent report of 66 patients who received a total of 684 ketamine infusions over 40 min at 0.5 mg/kg for the treatment of depression at Emory University found blood pressure changes that were only considered “small, well tolerated and clinically insignificant” (84), there have been rare elevations in blood pressure high enough to cause concern for individuals at risk for cardiovascular complications in several reports. Considering the limited quality data available at this time, we continue to strongly recommend treatment environments capable of cardiac monitoring with medically trained nurses and physicians until more high-quality safety data can be reviewed.

As noted earlier, ketamine frequently has significant transient effects on cognition, perception, and anxiety, even when administered to the healthy volunteers. Patients, not uncommonly, have some level of distress and anxiety during or immediately after the treatment. These are typically short-lived and resolve soon after infusion completion. Nevertheless, these can be disturbing to some patients and may interfere with their desire to continue treatment. For these reasons, clinicians should observe patients during and shortly after infusions until these symptoms resolve completely and should be prepared to provide appropriate behavioral management measures if needed.

Longer term risks of repeated ketamine use are largely extrapolated from a small population of ketamine abusers and animal studies, with understandable limitations. In retrospective observational studies, ketamine abusers have been reported to suffer from chronic cystitis, hepatotoxicity, and gall bladder pathology, along with psychiatric symptoms of impaired cognition and persistent dissociative effects (85). To date, it is not possible to determine the rates of such symptoms at the doses and frequencies most commonly used to treat depression. Perhaps the good news is that, to our knowledge, there is no clear evidence of a causative association between the doses and frequencies discussed here for the treatment of major depressive disorder with urinary complications. However, patients treated with maintenance ketamine should clearly be closely monitored until more data are collected. Last, there is the risk of fostering ketamine abuse or dependence in patients. Possibly because of its dissociative, stimulant, or analgesic effects, or its activity at opioid receptors, ketamine is a common drug of abuse in many regions of the world. Although we do not believe that this necessarily prohibits consideration of the drug for the treatment for appropriate patients, patients should be carefully screened for a history of substance use disorders.
and be followed closely for any signs of substance use disorder during the treatment series. At present, take-home ketamine dosing is not recommended because of the risks associated with the transient effects and the risk of abuse and diversion (83).

CONCLUSIONS
Growing evidence supports ketamine’s robust and prompt antidepressant effects, and recent findings suggest that the antidepressant effects may be extended for some period of time with continued treatment. However, there are many unanswered questions and concerns related to the drug’s practical use in the clinical management of patients. There are ongoing efforts to understand the mechanisms underlying ketamine’s effects on mood. Although the more immediate pharmacological effects of the drug remain somewhat in question, there is growing convergent evidence that it does involve some level of neuroplastic change that extends well beyond the presence of the drug in body. This is of specific interest clinically, as it suggests that there may be a unique window of opportunity to engage other psychosocial treatments while the brain is more “malleable” (86). Although studies related to optimal dose, route, and frequency of administration are now beginning to be published, there are extremely little high-quality data on which to base clinical opinions. At present, there is little doubt that the greatest amount of evidence exists for the 0.5 mg/kg dose provided i.v. over 40 min. However, future studies are likely to provide us with alternative dosing strategies with equivalent or possibly improved risk/benefit ratios. There is also a dearth of published data on the longer term benefits of the treatment. Several groups are now starting to present their clinical findings with relatively large numbers of patients receiving longer term ketamine treatment at meetings. Although the quality of these reports is not comparable to that of large, well-controlled clinical trials, it will be important to the field to see these reports in peer-reviewed publications at some point in the near future. The completion of several large phase-III trials with intranasal esketamine will provide results in the next year. This large database of both long and shorter term treatments will be directly applicable to the use of esketamine but will continue to leave questions regarding the use of racemic ketamine, especially delivered by other routes, doses, and frequencies.

There are extremely little published data related to the use of ketamine for disorders other than major depressive disorder at this time. The use of ketamine for these indications is admittedly intriguing, and possibly even promising, but we all should be aware of the limited published data on hand to support its use at this time. Looking to the future, we strongly recommend the formation of a centralized registry and database of ketamine use to allow for aggregated high-quality data collection, safety reports, and regulatory purposes. There are many inherent ethical challenges accompanying the use of an agent such as ketamine, but we believe that, with cautious rational use and development, it could serve a central role in the future of psychopharmacology.

AUTHOR AND ARTICLE INFORMATION
Drs. Sanacora and Katz are both with the Yale Department of Psychiatry, Yale University, New Haven CT, and the Yale Interventional Psychiatry Service, Yale New Haven Psychiatric Hospital, New Haven, CT. Send correspondence to Dr. Katz (rachel.katz@yale.edu).

Dr. Sanacora has received consulting fees from Alkermes, Allergan, BioHaven Pharmaceuticals Holding Company, Janssen, Merck, Sage Pharmaceuticals, Taisho Pharmaceuticals, Takeda, and Vistagen Therapeutics over the past 24 months. He has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Hoffman La-Roche, Johnson & Johnson, Merck & Co., and Servier over the past 24 months. Free medication was provided to Dr. Sanacora for an NIH-sponsored study by Sanofi-Aventis. In addition, he holds shares in BioHaven Pharmaceuticals Holding Company and is a co-inventor on a patent: “Glutamate Agents in the Treatment of Mental Disorders,” number 8778979. Dr. Katz reports no financial relationships with commercial interests.

REFERENCES
12. Popova D, Castrén E, Taira T: Chronic flutamide administration enhances synaptic plasticity and increases functional dynamics in hippocampal CA3-CAl synapses. Neuropharmacology 2017; 126:250–256
17. Yamakura T, Chavez-Noriega LE, Harris RA: Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 2000; 92:1144–1153
23. Liu J, Moghaddam B: Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J Pharmacol Exp Ther 1995; 274:1209–1215
30. Fukumoto K, Iijima M, Chaki S: The antidepressant effects of an mGlur5/3 receptor antagonist and ketamine require AMPA receptor stimulation in the nPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 2016; 41: 1046–1056
KETAMINE: A REVIEW FOR CLINICIANS


58. Malinovsky JM, Servin F, Cozian A, et al: Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administra-


60. Daly EJ, Singh JB, Fedgchin M, et al: Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2018; 75:139–148


66. Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A: Ketamine augmentation rapidly improves depression scores in inpa-


76. McGirr A, Berlim MT, Bond DJ, et al: Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-

77. Price RB, Nock MK, Charney DS, et al: Effects of intrave-


82. Liebe T, Li S, Lord A, et al: Factors influencing the cardiovascu-


86. Wilkinson ST, Wright D, Fasula MK, et al: Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom 2017; 86:162–167